<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PHENTERMINE HYDROCHLORIDE</span><br/>(phen-ter'meen)<br/><span class="topboxtradename">Ionamin, </span><span class="topboxtradename">Fastin, </span><span class="topboxtradename">Zantryl, </span><span class="topboxtradename">Adipex-P, </span><span class="topboxtradename">Obe-Nix-30<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">anorexiant</span><br/><b>Prototype: </b>Diethylpropion<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>8 mg, 30 mg, 37.5 mg tablets; 15 mg, 18.75 mg, 30 mg, 37.5 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Sympathetic amine with pharmacological similarity to amphetamine. Actions include CNS stimulation and blood pressure elevation.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Appetite suppression or metabolic effects along with diet adjustment result in weight loss in obese individuals.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short term (812 wk) adjunct for weight loss.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypertension, moderate-to-severe hypertension, advanced arteriosclerosis, cardiovascular disease; hyperthyroidism;
         known hypersensitivity to sympathetic amines; agitated states; history of drug abuse; during or within 14 d of administration
         of MAOI; concurrent administration of serotonin reuptake inhibitors (SSRIs); valvular heart disease; glaucoma; pregnancy (category
         C), lactation, or children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild hypertension, diabetes mellitus.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Obesity</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 8 mg t.i.d. 30 min before meals or 1537.5 mg q.d. before breakfast or 1014 h before retiring<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that at least 14 d have elapsed between the first dose of phentermine and the last dose of a MAO inhibitor.</li>
<li>Give 30 min before meals.</li>
<li>Do not administer if a SSRI is currently prescribed.</li>
<li>Store in a tight container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (urticaria, rash, erythema, burning sensation), chest pain, excessive sweating, clamminess, chills, flushing,
      fever, myalgia. <span class="typehead">CV:</span> Palpitations, tachycardia, arrhythmias, hypertension or hypotension, syncope, precordial pain, pulmonary hypertension. <span class="typehead">GI:</span> Dry mouth, altered taste, nausea, vomiting, abdominal pain, diarrhea, constipation, stomach pain. <span class="typehead">Endocrine:</span> Gynecomastia. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Bone marrow suppression, agranulocytosis</span>, leukopenia. <span class="typehead">Musculoskeletal:</span> Muscle pain. <span class="typehead">CNS:</span> Overstimulation, nervousness, restlessness, dizziness, insomnia, weakness, fatigue, malaise, anxiety, euphoria, drowsiness,
      depression, agitation, dysphoria, tremor, dyskinesia, dysarthria, confusion, incoordination, headache, change in libido. <span class="typehead">Skin:</span> Hair loss, ecchymosis. <span class="typehead">Special Senses:</span> Mydriasis, blurred vision. <span class="typehead">Urogenital:</span> Dysuria, polyuria, urinary frequency, impotence, menstrual upset. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">mao inhibitors</span>, <b>furazolidone</b> may increase pressor response resulting in hypertensive crisis. <span class="classification">tricyclic antidepressants</span> may decrease anorectic response. May decrease hypotensive effects of <b>guanethidine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorbed from the small intestine. <span class="typehead">Duration:</span> 414 h. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 1924 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for tolerance to the anorectic effect of the drug. Withhold drug and report to physician when this occurs.</li>
<li>Lab tests: Periodic CBC with differential and blood glucose.</li>
<li>Monitor periodic cardiovascular status, including BP, exercise tolerance, peripheral edema.</li>
<li>Monitor weight at least 3 times/wk.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take this drug late in the evening because it could cause insomnia.</li>
<li>Report immediately any of the following: Shortness of breath, chest pains, dizziness or fainting, swelling of the extremities.</li>
<li>Tolerance to the appetite suppression effects of the drug usually develops in a few weeks. Notify physician, but do not increase
            the drug dose.
         </li>
<li>Weigh yourself at least 3 times/wk at the same time of day with the same amount of clothing.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>